Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLQ | O75417 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15319795 | 0.85 | IDO1 (0.44) | SLC6A2SLC6A4SLC6A3IDO1DAO | |
| SCHEMBL267012 | 0.85 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3IDO1DAO | |
| SCHEMBL19481151 | 0.84 | IDO1 (0.43) | SLC6A2SLC6A4SLC6A3IDO1DAO | |
| SCHEMBL17329111 | 0.81 | IDO1 (0.59) | SLC6A2SLC6A4IDO1DAOPOLQ | |
| SCHEMBL320896 | 0.80 | IDO1 (0.50) | SLC6A2SLC6A4SLC6A3IDO1POLQ | |
| SCHEMBL12590726 | 0.79 | ALDH1A1 (0.41) | SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL7630645 | 0.79 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL31517195 | 0.79 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL327569 | 0.78 | IDO1 (0.52) | SLC6A2SLC6A4IDO1DAOPOLQ | |
| SCHEMBL16268467 | 0.78 | SCN8A (0.53) | SLC6A2SLC6A4SLC6A3IDO1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4276089-A2 | MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY | Universite De Moncton (CA) | 2023-11-15 | — | — | EP | disclosed |
| EP-3423429-B1 | MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY | UNIV DE MONCTON (CA) | 2023-07-12 | — | — | EP | disclosed |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| WO-2023283453-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| US-11225480-B2 | Malic enzyme inhibitors | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-01-18 | — | — | US | disclosed |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2021-04-22 | — | — | US | disclosed |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) | 2017-05-25 | — | — | US | disclosed |
| EP-2303270-B1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-05-17 | — | — | EP | disclosed |
| US-20160287607-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-10-06 | — | — | US | disclosed |
| US-9452973-B2 | Modulators of the relaxin receptor 1 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-09-27 | — | — | US | disclosed |
| US-20090197888-A1 | FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| WO-2009076166-A2 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009076173-A2 | FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| WO-2007146695-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | SLC6A2 4562/4885SLC6A4 4800/4885SLC6A3 4396/4885 |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | SLC6A2 3959/4885SLC6A4 2239/4885SLC6A3 3141/4885 |
| US-20160287607-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | RBP4, RBP1, LRAT | SLC6A2 722/4885SLC6A4 1212/4885SLC6A3 349/4885 |
| US-11225480-B2 | Malic enzyme inhibitors | ME1, RNASE1, ME2 | SLC6A2 4426/4885SLC6A4 4797/4885SLC6A3 3860/4885 |
| US-20090197888-A1 | FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | CTSC, PRSS1, SPINT2 | SLC6A2 2102/4885SLC6A4 570/4885SLC6A3 1477/4885 |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | HAVCR2, CD44, ENGASE | SLC6A2 3614/4885SLC6A4 3564/4885SLC6A3 3804/4885 |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | PRSS1, HPN, SPINT2 | SLC6A2 3311/4885SLC6A4 1469/4885SLC6A3 2578/4885 |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | RXFP1, RXFP2, RXFP3 | SLC6A2 1868/4885SLC6A4 1943/4885SLC6A3 2872/4885 |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | SLC6A2 3959/4885SLC6A4 2239/4885SLC6A3 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.